急性肾损伤生物标志物对于预测后续肾脏替代治疗需求的能力欠佳，但尚未使其失去价值。 - Suppr | 超能文献

相似文献

1

AKI biomarkers are poor discriminants for subsequent need for renal replacement therapy, but do not disqualify them yet.急性肾损伤生物标志物对于预测后续肾脏替代治疗需求的能力欠佳，但尚未使其失去价值。

Intensive Care Med. 2018 Jul;44(7):1156-1158. doi: 10.1007/s00134-018-5151-7. Epub 2018 Apr 12.

2

Acute kidney injury in sepsis.脓毒症相关性急性肾损伤。

Intensive Care Med. 2017 Jun;43(6):816-828. doi: 10.1007/s00134-017-4755-7. Epub 2017 Mar 31.

3

Biomarker strategies to predict need for renal replacement therapy in acute kidney injury.预测急性肾损伤患者肾脏替代治疗需求的生物标志物策略。

Semin Dial. 2011 Mar-Apr;24(2):124-31. doi: 10.1111/j.1525-139X.2011.00830.x.

4

Biomarkers in acute kidney injury (AKI).急性肾损伤 (AKI) 的生物标志物。

Best Pract Res Clin Anaesthesiol. 2017 Sep;31(3):331-344. doi: 10.1016/j.bpa.2017.10.003.

5

Management of Acute Kidney Injury and Acid-Base Balance in the Septic Patient.脓毒症患者急性肾损伤与酸碱平衡的管理。

Clin Chest Med. 2016 Jun;37(2):277-88. doi: 10.1016/j.ccm.2016.01.012. Epub 2016 Mar 8.

6

Pathophysiology and Clinical Work-Up of Acute Kidney Injury.急性肾损伤的病理生理学与临床检查

Contrib Nephrol. 2016;188:1-10. doi: 10.1159/000445460. Epub 2016 May 12.

7

[Traditional and novel reference index for the withdrawal of renal replacement therapy in patients with acute kidney injury].

Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2016 Mar;28(3):281-4.

8

Novel and conventional serum biomarkers predicting acute kidney injury in adult cardiac surgery--a prospective cohort study.预测成人心脏手术中急性肾损伤的新型及传统血清生物标志物——一项前瞻性队列研究

Crit Care Med. 2009 Feb;37(2):553-60. doi: 10.1097/CCM.0b013e318195846e.

9

Acute kidney injury after burn.烧伤后急性肾损伤

Burns. 2017 Aug;43(5):898-908. doi: 10.1016/j.burns.2017.01.023. Epub 2017 Apr 12.

10

The assessment of acute kidney injury in critically ill patients.危重症患者急性肾损伤的评估。

Eur J Intern Med. 2017 Nov;45:54-58. doi: 10.1016/j.ejim.2017.09.041. Epub 2017 Oct 2.

引用本文的文献

1

Mechanistic Aspects and Therapeutic Potential of Quercetin against COVID-19-Associated Acute Kidney Injury.槲皮素防治 COVID-19 相关性急性肾损伤的作用机制及治疗潜力。

Molecules. 2020 Dec 7;25(23):5772. doi: 10.3390/molecules25235772.

2

Biomarker-Guided Risk Assessment for Acute Kidney Injury: Time for Clinical Implementation?基于生物标志物的急性肾损伤风险评估：是否到了临床实施的时机？

Ann Lab Med. 2021 Jan;41(1):1-15. doi: 10.3343/alm.2021.41.1.1. Epub 2020 Aug 25.

3

Neutrophil Gelatinase-Associated Lipocalin Measured on Clinical Laboratory Platforms for the Prediction of Acute Kidney Injury and the Associated Need for Dialysis Therapy: A Systematic Review and Meta-analysis.

本文引用的文献

1

Biomarkers for prediction of renal replacement therapy in acute kidney injury: a systematic review and meta-analysis.用于急性肾损伤肾替代治疗预测的生物标志物：系统评价和荟萃分析。

Intensive Care Med. 2018 Mar;44(3):323-336. doi: 10.1007/s00134-018-5126-8. Epub 2018 Mar 14.

2

Validating benefit of biomarker-directed therapy for acute kidney injury: can you have your cake and eat it?验证生物标志物导向疗法对急性肾损伤的益处：鱼与熊掌能否兼得？

Intensive Care Med. 2017 Apr;43(4):578-580. doi: 10.1007/s00134-017-4710-7. Epub 2017 Feb 16.

3

Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients identified by biomarkers: the PrevAKI randomized controlled trial.